On May 30, 2025 Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc., reported its name change, to better align with its exclusive focus on proprietary innovative immuno-oncology medicines (Press release, Coherus Biosciences, MAY 30, 2025, View Source [SID1234653513]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The field of cancer immunotherapy has been reinvigorated by the promise and power of combination therapies. Coherus Oncology has the expertise and pipeline to become a significant player in this dynamic space and unlock the potential of these next-generation therapeutic approaches," said Jill O’Donnell-Tormey, Ph.D., Coherus Oncology board member. Dr. O’Donnell-Tormey is a Senior Advisor to the Cancer Research Institute and its former CEO.

"The next wave of breakthroughs in cancer immunotherapy will come from new mechanistic orthogonal approaches that synergize for optimal clinical efficacy. CCR8+ Tregs represent one of the most promising targets in cancers, enabling selective depletion of tumor immune suppression while mitigating the risk of breaking tolerance and leading to severe autoimmunity," said Alexander Rudensky, Ph.D., Coherus Scientific Advisory Board Co-Chair, Chairman and Member, Immunology Program, Sloan Kettering Institute, Lloyd Old Chair in Clinical Investigation Investigator, Howard Hughes Medical Institute Director, Ludwig Center for Cancer Immunotherapy Tri-Institutional Professor at MSKCC, The Rockefeller University and Cornell University.

"Coherus Oncology is firmly committed to the oncology community and developing the next generation of therapies focused on extending survival of cancer patients and improving their quality of life," said Theresa LaVallee, Ph.D., Chief Scientific and Development Officer of Coherus Oncology. "Our objective is to set new standards of cancer care with novel combinations that broadly target the immune system and resistance."

Our Novel Oncology Pipeline

Coherus Oncology is developing a portfolio of novel combination therapies with the aim of unlocking immune resistance to current therapies.

LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor, is the foundation of our immuno-oncology franchise. LOQTORZI is the only available FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC), and it is in development for the treatment of additional tumor types with the goal of being the PD-1/ICI backbone of future treatment combinations that may extend survival for patients.

CHS-114 is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. CHS-114 is currently being evaluated in combination with toripalimab in Phase 1b studies in patients with advanced solid tumors, including second-line head and neck squamous cell carcinoma and second-line gastric cancer.

Casdozokitug is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC). A randomized Phase 2 study is underway evaluating casdozokitug in combination with toripalimab and bevacizumab, versus toripalimab and bevacizumab, in patients with first-line advanced metastatic HCC. Squamous NSCLC continues as an area of clinical focus and future development.

Our Oncology Team & Board

Coherus Oncology is led and advised by a world-class team with deep expertise in oncology drug development and commercialization. The Scientific Advisory Board includes pioneers in the fields of Treg immunology, T cell exhaustion, and cytokine biology. The Board of Directors is comprised of industry leaders from the Cancer Research Institute, Merck, United Healthcare, Bristol Myers Squibb, as well as others. The breadth and depth of these perspectives provide Coherus Oncology with valuable insights to navigate the rapidly evolving oncology landscape and drive innovation to advance patient benefit and shareholder value.

Learn more about our executive team, Board of Directors, Scientific Advisory Board, and Strategic Advisors: View Source